Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)

Pfizer

Status: Completed

Conditions: Survival Status at Day 30 After the Last Intake

Study type: Observational

Funder types: Industry

Identifiers

NCT01840319

NRB1810005

Details and patient eligibility

About

The goal of this retrospective observational study is to collect only status survival data 30 days after the last dose of treatment of patients included in the initial protocol WYETH 3074A1-4448 / B1811030. The purpose is to estimate the survival status, 30 days after the last intake of tigecycline to patients hospitalized in ICU and treated by tigecycline.

Enrollment: 156 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients included in the previous study WYETH 3074A1-4448 then Pfizer B1811030 for which mortality status was not known at the closure of this previous study

Exclusion criteria

• Patients who has withdrawn their consent for the study WYETH3074A1-4448 then Pfizer B1811030.

Trial design

156 participants in 1 patient group

1

Description:

Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)